All In Biotech

Drug Trial Radar · NCT07282574

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)

A Multi-center, Double-blind, Placebo-controlled, Phase II Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489, a Monoacylglycerol Lipase Inhibitor, as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis

Last checked: Nov 19, 2026Latest source record: Oct 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 360 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

360

Planned (sponsor's estimate)

Start

Mar 10, 2026

Primary completion

May 30, 2028

Study completion May 30, 2030

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Dec 15, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to assess the efficacy of RO7268489 in adults with progressive multiple sclerosis (PMS) receiving ocrelizumab. After the end of the double-blind period, an open-label (OL) extension may allow eligible participants to receive open-label RO7268489.

Conditions

  • Progressive Multiple Sclerosis

Interventions

  • RO7268489Drug

    RO7268489 will be administered per schedule as specified in the arms.

  • OcrelizumabDrug

    Ocrelizumab will be administered per schedule as specified in the arms.

  • PlaceboDrug

    Placebo will be administered per schedule as specified in the arms.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time From Randomization to the First Occurrence of Composite Confirmed Disability Progression (cCPD) Confirmed for at Least 12 Weeks (cCDP12)Time frame: Up to approximately 110 weeks

Locations

114 sites in 12 countries. Site status is shown where the registry gives one.

  • Brain and Mind Centre

    Camperdown, New South Wales, Australia · Recruiting

  • Southern Neurology

    Kogarah, New South Wales, Australia · Recruiting

  • John Hunter Hospital

    New Lambton Heights, New South Wales, Australia · Recruiting

  • Box Hill Hospital

    Box Hill, Victoria, Australia · Recruiting

  • Austin Health

    Heidelberg, Victoria, Australia · Recruiting

  • Centro de Pesquisas Clinicas - CPCLIN

    São Paulo, São Paulo, Brazil · Recruiting

  • Hopital Neurologique Pierre Wertheimer

    Bron, France · Recruiting

  • Groupe Hospitalier Pitie-Salpetriere

    Paris, France · Recruiting

  • CHU Rennes - Hopital Pontchaillou

    Rennes, France · Recruiting

  • CHU Strasbourg Hpital Hautepierre

    Strasbourg, Bas Rhin, France · Recruiting

  • Hopital Caremeau

    Nîmes, Gard, France · Recruiting

  • Groupe Hospitalier Pellegrin

    Bordeaux, Gironde, France · Recruiting

  • Hopital Purpan

    Toulouse, Haute Garonne, France · Recruiting

  • Hopital Gui de Chauliac

    Montpellier, Herault, France · Recruiting

  • CHU Nantes - Hopital Nord Laënnec

    Saint-Herblain, Loire Atlantique, France · Recruiting

  • CHU Nancy Hôpital Central

    Nancy, Meurthe Et Moselle, France · Recruiting

  • CHU Hopital Gabriel Montpied

    Clermont-Ferrand, Puy De Dome, France · Recruiting

  • Charité Universitaetsmedizin Berlin - Campus Ch

    Berlin, Germany · Recruiting

  • Universitaetsklinikum Hamburg-Eppendorf

    Hamburg, Germany · Recruiting

  • Universitaetsklinikum Freiburg

    Freiburg im Breisgau, Baden-Wurttemberg, Germany · Recruiting

  • Universitaetsmedizin Mannheim

    Mannheim, Baden-Wurttemberg, Germany · Recruiting

  • Universitaetsklinikum Tuebingen

    Tübingen, Baden-Wurttemberg, Germany · Recruiting

  • Studienzentrum Neuropoint GmbH,

    Ulm, Baden-Wurttemberg, Germany · Recruiting

  • Universitaetsklinikum Ulm

    Ulm, Baden-Wurttemberg, Germany · Recruiting

  • Universitaetsklinikum Erlangen

    Erlangen, Bavaria, Germany · Recruiting

  • LMU-Campus Grosshadern

    Munich, Bavaria, Germany · Recruiting

  • Klinikum rechts der Isar der TU Muenchen

    Munich, Bavaria, Germany · Recruiting

  • Universitaetsklinikum Frankfurt Goethe-Universitaet

    Frankfurt am Main, Hesse, Germany · Recruiting

  • St. Josef-Hospital Universitaetsklinikum

    Bochum, North Rhine-Westphalia, Germany · Recruiting

  • Universitaetsklinikum Bonn AoeR

    Bonn, North Rhine-Westphalia, Germany · Recruiting

  • Universitaetsklinikum Duesseldorf

    Düsseldorf, North Rhine-Westphalia, Germany · Recruiting

  • Universitaetsklinkm Essen

    Essen, North Rhine-Westphalia, Germany · Recruiting

  • Universitaetsklinikum Carl Gustav Carus TU Dresden

    Dresden, Saxony, Germany · Recruiting

  • Universitaetsklinikum Leipzig

    Leipzig, Saxony, Germany · Recruiting

  • Clinexpert Kft.

    Budapest, Hungary · Recruiting

  • S-Medicon Egeszsegugyi Szolgaltato Kft.

    Budapest, Hungary · Recruiting

  • Semmelweis Egyetem

    Budapest, Hungary · Recruiting

  • Bajcsy-Zsilinszky Korhaz es Rendelointezet

    Budapest, Hungary · Recruiting

  • Budapesti Uzsoki Utcai Kórház

    Budapest, Hungary · Recruiting

  • Debreceni Egyetem Klinikai Kozpont Kenezy Gyula Campus

    Debrecen, Hungary · Recruiting

Showing 40 of 114 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.